Psoriasis

Dermata Therapeutics Inc (NASDAQ: DRMA) announced topline results from its Phase 1b trial of DMT310 for mild-to-moderate psoriasis.  The percentage of treatment responders in Physician's Global Assessment (PGA) with a score of 0 or 1 was 29.6% at Week 8. PGA is a scoring system used...

AnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP). GPP is a rare and extreme form of psoriasis characterized by the presence of sterile pustules. The 16-week data were presented at the 2021...

Novartis AG (NYSE: NVS) announced data from an international Phase 3b study of Cosentyx (secukinumab) in plaque psoriasis. Data showed that treatment with Cosentyx 300 mg in a 2 mL autoinjector (UnoReady pen) resulted in high efficacy and convenient administration.  The data...

Evelo Biosciences Inc (NASDAQ: EVLO) has announced data from its Phase 2 study of EDP1815 for mild and moderate psoriasis.  A statistically significant reduction in the Psoriasis Area and Severity Index (PASI) score from baseline at week 16 was observed in the study.  25%...

​​​​​vTv Therapeutics Inc (NASDAQ: VTVT) announced the results of a multiple ascending dose study evaluating HPP737 in healthy adults. HPP737 is an orally administered phosphodiesterase type 4 (PDE4) inhibitor. The 12-subject trial had two dose cohorts, 15mg and 20mg. Dose...

Brookline has initiated Dermata Therapeutics Inc's (NASDAQ: DRMA) coverage with a Buy rating and $14 price target. Analyst Kumaraguru Raja sees an upside of almost 164%. Dermata's pipeline includes DMT310, a once-weekly topical product for acne, psoriasis & rosacea, and...

Soligenix Inc (NASDAQ: SNGX) says that following the validation of synthetic hypericin's biologic activity, the Company will be expanding the therapy under the research name SGX302 into psoriasis. Related Content: Soligenix Stock Moves Higher On US Orphan Drug Tag For T-...

The European Commission has cleared UCB's (OTC: UCBJF) Bimzelx (bimekizumab) for moderate to severe plaque psoriasis in adults. UCB's confidence lies in head-to-head studies that pitted Bimzelx against Novartis AG's (NYSE: NVS) Cosentyx (secukinumab) and found...

The FDA has approved Novartis AG’s (NYSE: NVS) Cosentyx (secukinumab) to treat moderate to severe plaque psoriasis in pediatric patients six years and older and are candidates for systemic therapy or phototherapy. The approved dosing is 75 mg or 150 mg depending on the child...

Tucked in its Q1 earnings release, Eli Lilly And Co (NYSE: LLY) has scrapped its plans to seek approval for mirikizumab in psoriasis. The company decided not to enter the market despite the anti-IL-23p19 antibody outperforming Novartis AG’s (NYSE: NVS)...

Bristol-Myers Squibb Co (NYSE: BMY) has announced new data from its two Phase 3 trials POETYK PSO-1 and POETYK PSO-2 for deucravacitinib, its oral, selective TYK2 inhibitor for moderate to severe plaque psoriasis. Data were presented at the 2021 American Academy of Dermatology...

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has announced the presentation of new safety and efficacy data of roflumilast foam to treat scalp and body psoriasis. Data were presented in a late-breaking oral presentation at the American Academy of Dermatology Virtual Meeting...

Can-Fite BioPharma Ltd (NYSE: CANF) has expanded its Phase 2 COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomized, double-blind, placebo-controlled study evaluates Piclidenoson plus standard supportive care (SSC) vs. placebo plus SSC in...

Can-Fite BioPharma (NYSE: CANF) has initiated a series of preclinical studies required by regulators to support potential marketing registration filings for its drug candidates Piclidenoson and Namodenoson in the U.S. and Europe. As part of marketing applications in the U.S....